Abstract: A control system for an internal combustion engine having an exhaust gas recirculation device for recirculating a part of exhaust gases to an intake system of the engine is disclosed. An estimated exhaust gas recirculation amount is calculated using a neural network to which at least one engine operating parameter indicative of an operating condition of the engine is input. The neural network outputs an estimated value of an amount of exhaust gases recirculated by the exhaust gas recirculation device. At least one engine control parameter for controlling the engine is calculated based on the estimated exhaust gas recirculation amount.

Abstract: A spark gap protection device is provided. The device comprises a plurality of spark gaps and a plurality of windings. Each spark gap is connected to at least one winding which is inductively coupled to an associated winding connected to another spark gap so that, in use, a surge current flowing across a spark gap and through a winding connected to the spark gap induces a voltage in the associated inductively coupled winding connected to another spark gap. This forces the other spark gap to trigger, thereby distributing the surge current between the spark gaps.

Abstract: Novel hepatitis C virus (HCV) polypeptides are provided which are not encoded by the standard HCV open reading frame. These alternate reading frame polypeptides are useful, inter alia, in vaccine compositions, in diagnosing HCV infection, and as therapeutic targets.

Abstract: A navigation server capable of guiding a mobile subject such as an automobile by a navigation device, while appropriately evaluating the level of safeness of individual link in a disaster occurring area in consideration of the actual disaster condition is provided. According to the navigation server of the present invention, the links included in the disaster occurring area are extracted, and the cost of each of the extracted links is evaluated on the basis of the probe information. There is high probability that the spatial and temporal moving pattern of the automobile (a first mobile subject) represented by the probe information reflects the influence of the disaster. Therefore, the level of the safeness of individual link included in the disaster occurring area may be evaluated as the cost of individual link accurately in consideration of the actual disaster condition and road condition.

Abstract: An acidic group-containing polymer which has an acidic group such as sulfonic acid group, phosphoric acid group, and phosphonic acid group, and a proton acceptor which has a boiling point at 1 atmosphere higher than 100° C. and which functions as a medium for conducting proton dissociated from the acidic group are retained in pores of a porous member. Preferred examples of the proton acceptor include a salt structure composed of an anion and a cation derived from a basic organic compound, a basic organic compound, and a dissociation-facilitating polymer which facilitates dissociation of proton. Any one of the acidic group-containing polymer and the proton acceptor may be retained first, or both may be retained simultaneously.

Abstract: Method for diagnosis of autoimmune diseases of the GSE-type or associated with gluten sensitive enteropathy comprising taking a sample and testing the sample for antibodies against human tissue transglutaminase, tissue-specific transglutaminases, or other transglutaminases.

Abstract: Compositions and methods for the treatment of cancer, particularly melanoma, myeloma, small cell lung cancer, thymic lymphoma, T-cell lymphoma, B-cell lymphoma, osteosarcoma, and acute T-cell leukemia, are disclosed. Illustrative compositions include one or more anti-ganglioside antibodies and polynucleotides that encode such anti-ganglioside antibodies. These antibodies may be for example, hamster antibodies, chimeric human/hamster antibodies, or humanized antibodies. The disclosed compositions are useful, for example, in the treatment of cancer and can be used to induce apoptosis in a cancer cell.

Abstract: Antibodies that bind to a 40 kDa protein which is expressed on tumors, but is not expressed on normal adult hemopoietic cells are disclosed. Also disclosed are methods for production and the use of such antibodies.

Abstract: Methods and systems for translating models generated in one modeling environment into models that can be used in other modeling environments are disclosed. Models are created using different data formats in different modeling environments. These data formats are generally incompatible with each other. Therefore, the present invention provides a neutral data format that can store information relating to models generated in one modeling environment, and that can be used by other modeling environments to create their models. The present invention may export models created in one modeling environment into the neutral data format. The neutral data format may subsequently be imported into other modeling environments in which new models are generated using the information contained in the neutral data format. The present invention also provides animation of the newly generated models by animation clients via open animation interfaces that support multiple animation clients at a simultaneous time.

Abstract: A fuel cell system is provided which includes a fuel cell to which fuel gas and oxidizing gas are supplied to generate electricity, a purge valve which purges fuel gas discharged from the fuel cell, a dilutor which mixes the purged fuel gas with the oxidizing gas and purges the purged fuel gas mixed with the oxidizing gas into the atmosphere, and an ECU which stops supply of the oxidizing gas to the fuel cell so as to cause an idle stop and determines whether to permit the idle stop depending on a concentration of the fuel gas in the dilutor.

Abstract: The present invention provides methods for identifying druggable targets in assays that feature compositions, cells and/or organisms having structured viral non-coding RNAs (svRNAs) and an RNA interference (RNAi) pathway. Methods for identifying antiviral agents and creating vaccines are also featured. The invention further provides methods for inhibiting RNAi involving svRNAs or inhibitory derivatives thereof. The invention also provides compositions for delivering siRNA and miRNA molecules derived from svRNA loci and methods of use thereof. Therapeutic methods are also featured.

Abstract: Provided is an apparatus and method for preventing air baggage from getting lost using a radio frequency identification (RFID) system. The apparatus for preventing baggage from getting lost, change, or stolen in which a baggage tag storing baggage management information is attached to the baggage and a receipt tag storing the baggage management information is issued to a baggage owner, the apparatus includes: a tag reader reading the receipt tag and the baggage tag in a predetermined area; and a determiner determining whether the tag reader reads the receipt tag including the same baggage management information as the baggage management information of the baggage tag within a predetermined time before and after the tag reader reads the baggage tag. As a result, air baggage is quickly and exactly managed, costs is reduced, and foreign confidence of an airport is increased, thereby preventing baggage from getting lost and exchanged.

Abstract: A seal member is formed integrally on surfaces of a metal separator of a fuel cell. The seal member includes an outer seal and an inner seal provided on a surface of the metal separator. A plurality of closure seals are formed integrally with an inner edge of the inner seal. The closure seals close a space between the inner seal and a protrusion forming a fuel gas flow field.

Abstract: The present invention encompasses monoclonal antibodies that bind to lipoteichoic acid (LTA) of Gram positive bacteria. The antibodies also bind to whole bacteria and enhance phagocytosis and killing of the bacteria in vitro. The invention also provides antibodies having human sequences (chimeric, humanized and human antibodies). The invention also sets forth the variable regions of three antibodies within the invention and presents the striking homology between them.

Abstract: When a control device detects a request for stopping power generation of a fuel cell, electrical energy discharged from the fuel cell is supplied to an energy storage and other electrical devices such as an air compressor. At this time, electrical energy is supplied preferentially to the other electrical devices. Accordingly, discharge/charge losses in the energy storage can be reduced, compared to a technique in which an energy storage is charged preferentially at the time of stopping power generation of a fuel cell.

Abstract: A solid polymer electrolyte fuel cell (2) is formed from an electrode structure (7) and first and second separators (8, 9). The electrode structure (7) has a solid polymer electrolyte membrane (10), first and second electrode layers (11, 12), and first and second diffusion layers (13, 14). The first separator (8) forms a first gas passage (PH) through which a fuel gas (H) flows, and the second separator (9) forms a second gas passage (PA) through which an oxidizing gas (A) flows. A first jutting-out portion (15) of the solid polymer electrolyte membrane (10) and a second jutting-out portion (16) of the second diffusion layer (14) are joined together over the entire peripheries thereof via a cured adhesive layer (17), and the second jutting-out portion (16) is in a state in which it is impregnated by cured adhesive.

Abstract: A first aspect of the invention relates to a combination comprising a CDK inhibitor and 1-(2-C-cyano-2-dioxy-?-D-arabino-pentofuranosyl)-N4-palmitoyl cytosine, or a metabolite thereof. A second aspect of the invention relates to a pharmaceutical product comprising a CDK inhibitor and 1-(2-C-cyano-2-dioxy-?-D-arabino-pentofuranosyl)-N4-palmitoyl cytosine, or a metabolite thereof, as a combined preparation for simultaneous, sequential or separate use in therapy. A third aspect of the invention relates to a method of treating a proliferative disorder, said method comprising simultaneously, sequentially or separately administering a CDK inhibitor and 1-(2-C-cyano-2-dioxy-?-D-arabino-pentofuranosyl)-N4-palmitoyl cytosine, or a metabolite thereof, to a subject.

Abstract: A mechanism that allows firmware to be updated in a secure manner is discussed. Two attributes are used in the actual ROM to refer to a Virtual ROM module. The two attributes are a version attribute and a reference to a separate module that is capable of validating updates. The update process updates the message digest associated with the first Virtual ROM module and the version attribute associated with the first Virtual ROM module. The update process also produces a new copy of the corresponding file (that may be located on the local disk) that when hashed will “match” the new message digest.

Abstract: A system and method of exposing debugging information in a graphical modeling and execution environment is disclosed. The present invention allows a user to view debugging information in the same window as the graphical view of the model being executed. Debugging data is associated with relevant components of the model displayed in the graphical view. A separate execution list view shows the methods called during the execution of the block diagram in the current time step up until the current point in execution. User-set breakpoints and conditional breakpoints may be set in both the model view and the execution list view. Values may be obtained for all of the displayed methods. The debugging tool may be implemented by using it in conjunction with a graphical modeling and execution environment, such as a block diagram environment or state diagram environment.

Abstract: Based at least in part on an understanding of the mechanisms by which small RNAs (e.g., naturally-occurring miRNAs) mediate RNA silencing in plants, rules have been established for determining, for example, the degree of complementarity required between an RNAi-mediating agent and its target, i.e., whether mismatches are tolerated, the number of mismatches tolerated, the effect of the position of the mismatches, etc. Such rules are useful, in particular, in the design of improved RNAi-mediating agents which allow for more exact control of the efficacy of RNA silencing.